Deals
The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Sanofi announced it is acquiring Synthorx for $68 per share in cash, a value of $2.5 billion. The deal has been unanimously approved by both companies’ boards.
Ardelyx, Inc. has announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.25 per share, before underwriting discounts and commissions, for gross proceeds of $125,000,000.
4TEEN4 Pharmaceuticals GmbH announced the closing of a EUR 6.9 million Series A financing round.
Fundraising will support the expansion of Hummingbird Bioscience’s discovery pipeline and rapid development of its portfolio of targeted antibody therapeutics
Bpifrance and Pfizer Ventures co-led international investor syndicate
The company will further develop its high-resolution spinal cord stimulation focal pain therapy and perform clinical studies
The merger is an effort on the part of Astellas to strengthen its genetic medicine and gene therapy business.
Since its foundation Cambridge Innovation Capital has attracted £1 billion of investment into Cambridge companies, highlighting its dominant position at the heart of the innovation ecosystem
€8 million acquisition brings a wide range of revenue-generating products in orthopaedic, spine, dental and sports surgery
Proteros biostructures GmbH announced that Rodin Therapeutics, Inc., a Boston, MA based biotech company developing novel, small molecule therapeutics for synaptopathies has been acquired by Alkermes plc, a global biopharmaceutical company headquartered in Dublin, Ireland.